Published : Aug-2017
No. of Pages : 65
1. Dynamic Market Forecast Overview 5
1.1 Related Reports 6
1.2 Upcoming Related Reports 7
2. Executive Summary 8
2.1 Key Events in Update 9-10
2.2 Updates to Treatment Algorithms 11
2.3 Clinical Trial Landscape Updates 12-13
2.4 Pipeline Landscape Updates 14
2.5 Market Insight on Key Events 15
3. Event 1: Market Dynamics Shift in Frontline NSCLC 16
3.1 Key Updates to the Frontline Non-squamous Setting 17
3.2 Merck & Co., Keytruda (pembrolizumab) 18-19
3.3 AstraZeneca, Imfinzi (durvalumab) + tremelimumab 20-21
3.4 Pfizer and Merck KGaA , Bavencio (avelumab) 22
3.5 Roche, Tecentriq (atezolizumab) 23
3.6 Novartis, Tafinlar (dabrafenib) + Mekinist (trametinib) 24
3.7 Additional Clinical Trial Updates- Frontline Setting 25-26
3.8 Summary/Trends 27
3.9 Sources 28
4. Event 2: Weak Competition in the EGFRm+ Segment Creates Opportunity for Tagrisso 29
4.1 Key Updates to the EGFRm+ Segment 30
4.2 AstraZeneca, Tagrisso (osimertinib) 31-33
4.3 Pfizer, dacomitinib 34
4.4 Additional Clinical Trial Updates- EGFRm+ Setting 35
4.5 Summary/Trends 36
4.6 Sources 37
5. Event 3: New SOC Anticipated in the ALKm+ 1L Setting 38
5.1 Key Updates to the ALKm+ Setting 39
5.2 Roche, Alecensa (alectinib) 40
5.3 Takeda, Alunbrig (brigatinib) 41
5.4 Pfizer, lorlatinib 42
5.5 Summary/Trends 43
5.6 Sources 44
6. Other Events of Interest 45
6.1 Various Developers 46-47
6.2 Sources 48
7. Dynamic Market Forecast Highlights 49
7.1 Updates to Frontline NSCLC Segment 50
7.2 Updates to EGFRm+ NSCLC Segment 51
7.3 Updates to ALKm+ NSCLC Segment 52
7.4 Selected Additional Forecast Updates 53
8. Events Calendar 54
8.1 Key Clinical Events Expected in Q4 2017 55-56
9. Appendix 57
9.1 Methodology 58
9.2 Primary Research 59-60
9.3 About the Authors 61-62
9.4 About GlobalData 63
9.5 Contact Us 64
9.6 Disclaimer 65
